Phase II ZUMA-1: Interim Analysis of Anti-CD19 CAR T-Cell Therapy in Patients With Refractory Aggressive DLBCL

December 3-6, 2016; San Diego, California
Interim analysis reported significantly higher ORR and markedly greater CR with KTE-C19 vs historical rates in chemorefractory patients with DLBCL.
Format: Microsoft PowerPoint (.ppt)
File Size: 602 KB
Released: December 9, 2016


This activity is supported by educational grants from
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics

Related Content

Laurie Cohen, MD, on when and how to retest for GH deficiency, how soon to start GH replacement in cancer survivors from Clinical Care Options (CCO)

Laurie E. Cohen, MD Released: April 22, 2021

Danielle Friedman, MD, on adipose dysfunction, insulinopenia, obesity, and diabetes after irradiation in cancer survivors

Danielle N. Friedman, MD, MS Released: April 22, 2021

Expert slides on biologic principles, indications, and clinical biomarkers for immune checkpoint inhibitors, from Clinical Care Options (CCO)

Sandip P. Patel, MD Released: April 16, 2021

Expert slides on multidisciplinary management of immune-related adverse events associated with checkpoint inhibitors, from Clinical Care Options (CCO)

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: April 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.